160886-95-3

Basic information

• Product Name: Benzenebutanol, b-amino-
• CAS NO: 160886-95-3
• Molecular Formula: C10H15NO
• Molecular Weight: 165.235
• Mol File: 160886-95-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenebutanol, b-amino-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanol, b-amino-(160886-95-3)
• EPA Substance Registry System: Benzenebutanol, b-amino-(160886-95-3)

Safety Data

• Hazardous Substances Data: 160886-95-3(Hazardous Substances Data)

Upstream product

• 100-42-5 styrene 
• 940290-40-4 ethyl 2-((4-methoxyphenyl)amino)-4-phenylbutanoate 
• 46460-23-5 ethyl L-2-amino-4-phenylbutyrate 
• 67753-90-6 9-phenethyl-9-bora-bicyclo[3.3.1]nonane 
• 53646-91-6 3-phenyl-3,6-dihydro-1,2-dioxine 
• 1515-78-2 buta-1,3-dien-1-ylbenzene 

Downstream Products

• 344359-39-3 2-(1-hydroxymethyl-3-phenyl-propylamino)-1-phenyl-ethanone 
• 344427-65-2 N-[3-cyano-1-(1-hydroxymethyl-3-phenyl-propyl)-4-phenyl-1H-pyrrol-2-yl]-formamidine 
• 344359-47-3 2-amino-1-(1-hydroxymethyl-3-phenyl-propyl)-4-phenyl-1H-pyrrole-3-carbonitrile 
• 21176-73-8 4-phenethyl-thiazolidine-2-thione 
• 21176-69-2 4-phenethyl-oxazolidine-2-thione 

Relevant articles and documents

A domino Kornblum-DeLaMare/aza-Michael reaction of 3,6-dihydro-1,2-dioxines and application to the synthesis of the ceramide transport inhibitor (±)-HPA-12

A Kornblum-DeLaMare/aza-Michael reaction of 3,6-dihydro-1,2-dioxines with primary and secondary amines has been developed which affords 4-hydroxy-3-aminoketones. The aza-Michael products were reduced using non-selective NaBH4/MeOH or diastereoselective (up to 92:8) SnCl4/NaBH4 conditions yielding (1R?,3S?)-3-amino-1,4-diols in up to 97% and 70% yield respectively. The major reduction product was converted in two steps to (±)-HPA-12, which is an inhibitor of the cytosolic ceramide transporting protein.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.